Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Shire’s HAE drug Takhzyro gets green light in the US
Shire’s HAE drug Takhzyro gets green light in the US
Shire’s Takhzyro has been approved in the US for the prevention of attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Roche signs inclacumab deal with GBT
Roche signs inclacumab deal with GBT
Roche has sold off rights to inclacumab to Global Blood Therapeutics, which intends to develop the treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).
A New Way To Tackle Aging Could Have The Potential To Upend A $20 Billion Market
A New Way To Tackle Aging Could Have The Potential To Upend A $20 Billion Market
A new anti-aging therapeutic in the clinical pipeline could stand to disrupt multibillion-dollar legacy franchises like AbbVie’s Humira and Amgen’s Enbrel.
Life expectancy declines seen in U.S. and other high-income countries
Life expectancy declines seen in U.S. and other high-income countries
(Reuters Health) - Life expectancy is declining in high-income countries worldwide, driven in part by the effects of the opioid epidemic on younger adults in the U.
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
BRISTOL and COPENHAGEN, 17 August 2018 ­- Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit...
FDA approves first drug for neurotrophic keratitis, a rare eye disease
FDA approves first drug for neurotrophic keratitis, a rare eye disease
The U.
Candidate for universal flu vaccine protects against multiple strains
Candidate for universal flu vaccine protects against multiple strains
PHILADELPHIA--A universal flu vaccine that protects people against most influenza strains is one step closer to reality, with a study from the Perelman School of Medicine at the University of Pennsylv...
Toxin at heart of drug recall shows holes in medical safety net
Toxin at heart of drug recall shows holes in medical safety net
SHANGHAI/LONDON (Reuters) - A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators’ ability to detect r...
Measles epidemic in Europe hits record high, World Health Organisation warns
Measles epidemic in Europe hits record high, World Health Organisation warns
The measles epidemic sweeping Europe has reached an eight-year high, with more than 41,000 cases reported in the first six months of the year, the World Health Organisation (WHO) has warned.
NIH starts Phase l trial of rZIKV/D4Δ30-713 for Zika virus infection
NIH starts Phase l trial of rZIKV/D4Δ30-713 for Zika virus infection
The US National Institutes of Health (NIH) has started a Phase l clinical trial of rZIKV/D4Δ30-713 vaccine for the prevention of Zika virus infection.
U.S. health secretary says agency can eliminate drug rebates
U.S. health secretary says agency can eliminate drug rebates
WASHINGTON (Reuters) - U.
How the humble cabbage can stop cancers
How the humble cabbage can stop cancers
Scientists say they have discovered why some vegetables - including cabbage, broccoli and kale - can reduce the risk of bowel cancers.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand